PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17785681-0 2007 FK506, a calcineurin inhibitor, prevents cadmium-induced testicular toxicity in mice. Tacrolimus 0-5 calcineurin binding protein 1 Mus musculus 9-30 12100723-9 2002 FK506, a calcineurin inhibitor, and nifedipine, a calcium channel inhibitor, inhibited not only the expression of TNF-alpha and CD40L, but also the up-regulation of CD80 on irradiated A20-HL cells. Tacrolimus 0-5 calcineurin binding protein 1 Mus musculus 9-30 16084678-8 2005 The present findings suggest that these two calcineurin inhibitors have a protective effect against acoustic injury of the cochlea, whereas the non-calcineurin inhibitor, rapamycin, not only has no effect against acoustic injury, but rather blocked the effect of FK506. Tacrolimus 263-268 calcineurin binding protein 1 Mus musculus 44-65 11773940-5 2001 Treatment with calcineurin inhibitor FK506 (0.5 or 1.0 mg/kg/day) from the age of four to eight weeks attenuated cardiac hypertrophy without beneficially affecting cardiac function. Tacrolimus 37-42 calcineurin binding protein 1 Mus musculus 15-36 33777956-0 2021 Treatment With Calcineurin Inhibitor FK506 Attenuates Noise-Induced Hearing Loss. Tacrolimus 37-42 calcineurin binding protein 1 Mus musculus 15-36 9678635-0 1998 A calcineurin inhibitor, FK506, blocks voltage-gated calcium channel-dependent LTP in the hippocampus. Tacrolimus 25-30 calcineurin binding protein 1 Mus musculus 2-23 29266762-1 2018 Calcineurin inhibitor toxicity (CNT) is a frequent occurrence in transplanted renal grafts and autochthone kidneys from patients undergoing long-term treatment with calcineurin inhibitors, notably cyclosporin A (CsA) and tacrolimus. Tacrolimus 221-231 calcineurin binding protein 1 Mus musculus 0-21 34278483-1 2021 As a calcineurin inhibitor, tacrolimus is commonly used as a first-line immunosuppressant in organ transplant recipients. Tacrolimus 28-38 calcineurin binding protein 1 Mus musculus 5-26 34809463-3 2021 Harnessing fungal calcineurin-inhibitor crystal structures, we recently developed a less immunosuppressive FK506 analog, APX879, with broad-spectrum antifungal activity and demonstrable efficacy in a murine model of invasive fungal infection. Tacrolimus 107-112 calcineurin binding protein 1 Mus musculus 18-39 33273604-4 2020 Administration of FK506, a calcineurin inhibitor, in the heterozygous fetuses improved bone mineral content (BMC) of the neonates, although it did not save the neonates from the lethal effects of the mutation, whereas rapamycin, an mTOR inhibitor, reduced BMC, suggesting that mTOR signaling is involved in the bone mineralization of heterozygous mutants. Tacrolimus 18-23 calcineurin binding protein 1 Mus musculus 27-48 32151541-0 2020 Tacrolimus, a calcineurin inhibitor, promotes capsaicin-induced colonic pain in mice. Tacrolimus 0-10 calcineurin binding protein 1 Mus musculus 14-35 32151541-2 2020 Since the clinical use of calcineurin-inhibiting immunosuppressants is commonly associated with chronic diarrhea, we examined if tacrolimus, a calcineurin inhibitor, promotes TRPV1-dependent colonic hypersensitivity in mice. Tacrolimus 129-139 calcineurin binding protein 1 Mus musculus 143-164 28584011-2 2017 We and others have reported that cyclosporine A and tacrolimus decrease anti-inflammatory regulatory T cells and increase proinflammatory interleukin-17-producing T cells; therefore, we hypothesized that inhibition of these effects using noncellular therapies would prevent the hypertension, endothelial dysfunction, and renal glomerular injury induced by calcineurin inhibitor therapy. Tacrolimus 52-62 calcineurin binding protein 1 Mus musculus 356-377 27754593-2 2017 Here, we assessed age-specific effects of the calcineurin inhibitor tacrolimus (TAC) in a murine transplant model and assessed its clinical relevance on human T cells. Tacrolimus 68-78 calcineurin binding protein 1 Mus musculus 46-67 20434440-0 2010 The calcineurin inhibitor, FK506, does not alter glutamate transport in the ischaemic mouse retina. Tacrolimus 27-32 calcineurin binding protein 1 Mus musculus 4-25 23406906-1 2013 INTRODUCTION: This study investigated whether the calcineurin inhibitor, tacrolimus, suppresses receptor activator of NF-kappaB ligand (RANKL) expression in fibroblast-like synoviocytes (FLS) through regulation of IL-6/Janus activated kinase (JAK2)/signal transducer and activator of transcription-3 (STAT3) and suppressor of cytokine signaling (SOCS3) signaling. Tacrolimus 73-83 calcineurin binding protein 1 Mus musculus 50-71 21094856-1 2010 Tacrolimus (Tac, FK506) is a widely used T-cell-targeted immunosuppression drug known as a calcineurin inhibitor. Tacrolimus 0-10 calcineurin binding protein 1 Mus musculus 91-112 21094856-1 2010 Tacrolimus (Tac, FK506) is a widely used T-cell-targeted immunosuppression drug known as a calcineurin inhibitor. Tacrolimus 17-22 calcineurin binding protein 1 Mus musculus 91-112 28253495-3 2017 Calcineurin, a phosphatase, negatively regulates various channel functions including TRPV1, and calcineurin inhibitor-induced pain syndrome by tacrolimus, a calcineurin inhibitor, used as an immunosuppressant, has been a clinical problem. Tacrolimus 143-153 calcineurin binding protein 1 Mus musculus 96-117 28253495-3 2017 Calcineurin, a phosphatase, negatively regulates various channel functions including TRPV1, and calcineurin inhibitor-induced pain syndrome by tacrolimus, a calcineurin inhibitor, used as an immunosuppressant, has been a clinical problem. Tacrolimus 143-153 calcineurin binding protein 1 Mus musculus 157-178 26198442-5 2015 OBJECTIVE: To investigate whether the glucocorticosteroid dexamethasone and the calcineurin inhibitor tacrolimus could affect TSLP expression induced by TNF-alpha in lesional keratinocytes of AD. Tacrolimus 102-112 calcineurin binding protein 1 Mus musculus 80-101 21963515-0 2011 The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Tacrolimus 26-36 calcineurin binding protein 1 Mus musculus 4-25